Dashboard
Manage Tickers

BMRNBIOMARIN PHARMACEUTICAL INC

Nasdaq biomarin.com


$ 83.65 $ -0.45 (-0.54 %)    

Monday, 09-Sep-2024 15:30:30 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 453.46 $ 0.93 (0.21 %)
DIA $ 408.80 $ 1.48 (0.36 %)
SPY $ 545.57 $ 0.90 (0.17 %)
TLT $ 99.95 $ 0.57 (0.57 %)
GLD $ 231.35 $ 0.09 (0.04 %)
$ 84.08
$ 84.10
$ 83.62 x 143
-- x --
$ 83.50 - $ 84.80
$ 73.68 - $ 99.56
1,580,812
na
16.01B
$ 0.66
$ 62.39
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-05-2024 06-30-2024 10-Q
2 04-26-2024 03-31-2024 10-Q
3 02-26-2024 12-31-2023 10-K
4 11-02-2023 09-30-2023 10-Q
5 08-02-2023 06-30-2023 10-Q
6 04-28-2023 03-31-2023 10-Q
7 02-27-2023 12-31-2022 10-K
8 10-28-2022 09-30-2022 10-Q
9 08-04-2022 06-30-2022 10-Q
10 04-29-2022 03-31-2022 10-Q
11 02-25-2022 12-31-2021 10-K
12 10-29-2021 09-30-2021 10-Q
13 07-30-2021 06-30-2021 10-Q
14 04-30-2021 03-31-2021 10-Q
15 02-26-2021 12-31-2020 10-K
16 11-06-2020 09-30-2020 10-Q
17 08-05-2020 06-30-2020 10-Q
18 05-01-2020 03-31-2020 10-Q
19 02-27-2020 12-31-2019 10-K
20 10-29-2019 09-30-2019 10-Q
21 08-02-2019 06-30-2019 10-Q
22 04-29-2019 03-31-2019 10-Q
23 02-28-2019 12-31-2018 10-K
24 10-26-2018 09-30-2018 10-Q
25 08-03-2018 06-30-2018 10-Q
26 04-27-2018 03-31-2018 10-Q
27 02-26-2018 12-31-2017 10-K
28 10-31-2017 09-30-2017 10-Q
29 08-02-2017 06-30-2017 10-Q
30 05-04-2017 03-31-2017 10-Q
31 02-27-2017 12-31-2016 10-K
32 11-03-2016 09-30-2016 10-Q
33 08-08-2016 06-30-2016 10-Q
34 05-02-2016 03-31-2016 10-Q
35 02-29-2016 12-31-2015 10-K
36 11-02-2015 09-30-2015 10-Q
37 08-05-2015 06-30-2015 10-Q
38 05-05-2015 03-31-2015 10-Q
39 03-02-2015 12-31-2014 10-K
40 10-28-2014 09-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

cantor-fitzgerald-reiterates-overweight-on-biomarin-pharmaceutical-maintains-110-price-target
Cantor Fitzgerald Reiterates Overweight on...
09/09/2024 15:32:45

Cantor Fitzgerald analyst Olivia Brayer reiterates Biomarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and maintains $11...

fda-battles-backlog-of-drug-factory-inspections-since-covid-19
FDA Battles Backlog of Drug Factory Inspec...
09/06/2024 15:52:51

FDA faces inspection backlog with serious public health implications, as critical drug manufacturing plants remain unchecked.

jp-morgan-maintains-overweight-on-biomarin-pharmaceutical-raises-price-target-to-120
JP Morgan Maintains Overweight on Biomarin...
09/05/2024 16:05:09

JP Morgan analyst Jessica Fye maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and raises the price target ...

rbc-capital-reiterates-sector-perform-on-biomarin-pharmaceutical-maintains-100-price-target
RBC Capital Reiterates Sector Perform on B...
09/05/2024 15:56:19

RBC Capital analyst Luca Issi reiterates Biomarin Pharmaceutical (NASDAQ:BMRN) with a Sector Perform and maintains $100 pric...

scotiabank-maintains-sector-perform-on-biomarin-pharmaceutical-raises-price-target-to-95
Scotiabank Maintains Sector Perform on Bio...
09/05/2024 15:14:12

Scotiabank analyst George Farmer maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Sector Perform and raises the price ...

biomarin-restructures-outlines-roadmap-to-4b-revenues-by-2027
BioMarin Restructures, Outlines Roadmap To...
09/05/2024 13:51:16

BioMarin aims for $4 billion revenue by 2027, focusing on gene therapy and enzyme treatments, with a robust pipeline set to enh...

piper-sandler-maintains-overweight-on-biomarin-pharmaceutical-raises-price-target-to-122
Piper Sandler Maintains Overweight on Biom...
09/05/2024 13:45:53

Piper Sandler analyst Christopher Raymond maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and raises the p...

deep-dive-into-biomarin-pharmaceutical-stock-analyst-perspectives-14-ratings
Deep Dive Into Biomarin Pharmaceutical Sto...
09/05/2024 13:00:53

truist-securities-maintains-buy-on-biomarin-pharmaceutical-lowers-price-target-to-118
Truist Securities Maintains Buy on Biomari...
09/05/2024 12:12:54

Truist Securities analyst Robyn Karnauskas maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Buy and lowers the price t...

ascendis-pharma-faces-challenges-with-skytrofa-and-yorvipath-pricing-analysts-weigh-in
Ascendis Pharma Faces Challenges With Skyt...
09/04/2024 21:02:35

Ascendis Pharma reported disappointing Q2 sales of $38.76 million, missing the consensus of $92.7 million. Key updates included...

biomarin-pharmaceutical-shares-resume-trade
BioMarin Pharmaceutical Shares Resume Trade
09/04/2024 17:30:28

trading-halt-halt-status-updated-at-12500-pm-et-quotation-resumption-news-and-resumption-times
Trading Halt: Halt status updated at 1:25:...
09/04/2024 17:25:08

from-biomarin-investor-day-co-provides-new-corporate-strategy-and-introduces-2027-financial-guidance-sees-fy27-total-revenues-4b-updated-corporate-strategy-includes-implementation-of-500m-cost-transformation-program-voxzogo-expected-data-readout-targeted-in-2026-potential-approval-in-2027-full-year-2024-guidance-reaffirmed
From BioMarin Investor Day, Co Provides Ne...
09/04/2024 17:03:56

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) hosted an Investor Day earlier today, where President and Chief Executive Officer Al...

biomarin-pharmaceutical-says-co-will-be-entitled-to-draw-funds-at-its-discretion-until-revolving-credit-facility-matures-on-aug-28-2029
BioMarin Pharmaceutical Says Co Will Be En...
09/04/2024 16:58:13

- SEC Filing

biomarin-pharmaceutical-says-on-aug-28-entered-into-credit-agreement-for-up-to-600m-in-revolving-loans
BioMarin Pharmaceutical Says On Aug 28, En...
09/04/2024 16:56:58

- SEC Filing

trading-halt-halted-at-103000-am-et---trading-halt-halt-news-pending
Trading Halt: Halted at 10:30:00 a.m. ET -...
09/04/2024 14:30:04

biomarin-plans-to-reduce-its-global-workforce-by-approximately-225-employees
BioMarin Plans To Reduce Its Global Workfo...
08/28/2024 21:08:28

he Company decided to reduce its workforce in connection with organizational redesign efforts as well as the Company’s updated ...

piper-sandler-maintains-overweight-on-biomarin-pharmaceutical-maintains-107-price-target
Piper Sandler Maintains Overweight on Biom...
08/27/2024 15:28:42

Piper Sandler analyst Christopher Raymond maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and maintains $1...

stifel-maintains-buy-on-biomarin-pharmaceutical-raises-price-target-to-115
Stifel Maintains Buy on Biomarin Pharmaceu...
08/21/2024 16:25:30

Stifel analyst Paul Matteis maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Buy and raises the price target from $112...

bmrn---analyzing-biomarin-pharmaceuticals-short-interest
(BMRN) - Analyzing Biomarin Pharmaceutical...
08/21/2024 16:00:25

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION